CAMMA-2

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

More Information

Trial Status
Active, Not Recruiting
Trial Phase
Phase 1/2
Enrollment
90 patients (estimated)
Sponsors
Hoffmann-La Roche
Tags
Bispecific Antibody, CD3, FCRH5
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1308
NCT Identifier
NCT05535244

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.